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1. Introduction
Gastric emptying of dosage forms is an extremely variable process and ability to prolong and control the emptying 
time is a valuable asset for dosage forms, which reside in the stomach for a longer period of time than conventional dosage  
forms.  Several  difficulties  are  faced  in  designing  controlled  release  systems  for  better  absorption  and  enhanced 
bioavailability. One of such difficulties is the inability to confine the dosage form in the desired area of the gastrointestinal  
tract. Drug absorption from the gastrointestinal tract is a complex procedure and is subject to many variables. It is widely  
acknowledged that the extent of gastrointestinal tract drug absorption is related to contact time with the small intestinal  
mucosa1. Thus, small intestinal transit time is an important parameter for drugs that are incompletely absorbed. Retention of  
drug  delivery  systems  in  the  stomach  prolongs  overall  gastrointestinal  transit  time,  thereby  resulting  in  improved 
Abstract
Metformin hydrochloride floating tablets were prepared by wet granulation method by 
using optimized concentrations of gas generating agents, binding agents and natural  
gums as polymers like gum kondagogu and gum karaya. The formulations F1-F4 with 
concentrations 2-3.5% were prepared to optimize binding agent and formulations F5-
F7 with  concentrations  15-20% to  optimize  gas  generating  agent  where  optimum 
percentage of binding agent was found around 2.3% and gas generating agent was 
found around 17.25% to get quick floating lag time. The prepared granules evaluated 
for various parameters showed good results in which the Carr’s index, hausner ratio 
and angle  of  repose,  the values were found in between 9.05-16.78,  1.02-1.46 and 
23.17-32.64  respectively.  All  compressed  formulations  were  evaluated  for  various 
parameters and results of hardness, friability, drug content, were found around 7.1-
8.8kg/cm2, 0.56-1.48% and 499.3-499.8mg respectively. The tablets prepared by these 
granules  of  two  natural  gums as  polymers  showed  desired  floating properties.  F6 
formulation containing gum kondagogu and F11 formulation containing gum karaya 
showed good release retardation with release 99.42% and 99.75% respectively after 
12 hours in in vitro drug release studies. Formulations F6 and F11 after stability studies 
showed good results proving stable. In vivo studies also showed good correlation with 
the results of in vitro and X-ray pictograms proved the formulations is stable in vivo. 
Formulations F6 and F11 contains natural gums Kondagogu and karaya with 17.25% 
concentration  were  considered  as  best  formulation  as  they  showed  good  release 
retardation and, in release kinetic studies the n-value found appropriate for controlled 
release formulations.
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bioavailability.
The controlled gastric retention of solid dosage forms may be achieved by the mechanisms of mucoadhesion,  
floatation2, sedimentation, expansion, modified shape systems3, or by the simultaneous administration of pharmacological 
agents that delay gastric emptying. 
Metformin  Hydrochloride4-5 is  an  oral  anti-hyperglycemic  drug  used  in  the  management  of  type  2  diabetes. 
Metformin  Hydrochloride  (N,  N-dimethylimidodicarbonimidic  diamide  mono  hydrochloride)  is  not  chemically  or  
pharmacologically  related  to  sulfonylureas,  thiazolidinediones,  or  α-glucosidase  inhibitors.  It  is  a  white  to  off-white 
crystalline compound with a molecular formula of C4H12ClN5 (monohydrochloride) and a molecular weight of 165.63. 
Metformin Hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The pKa 
of Metformin Hydrochloride is 12.4. The pH of a 1% aqueous solution of Metformin Hydrochloride is 6.68.
Gum Karaya, often known as Sterculia gum, is the dried exudation of the “Sterculia Urens” tree and other species 
of Sterculia and belong to Sterculiaceae family6. The tree is native to India. The highest grade of Gum Karaya is white, 
translucent and almost free from bark. Powdered Gum Karaya is white to grayish white. Powdered gum karaya swells in 
cold  water  to  an  extent  that  a  3  to  4% solution  will  produce  a  heavy gel  of  uniform smoothness  and  texture.  Gum  
Kondagogu is a natural gum exudates7 obtained from stems and branches of “Cochlospermum gossypium” and belongs to 
Bixaceae family. It occurs as pale brown to brown in color. The specific rotation is 53.5 (±7.37). The water binding capacity 
for gum kondagogu is 35.1 mL g-1. It is swellable in water.
Here an attempt was made to prepare and evaluate controlled release floating drug delivery systems of metformin 
with gum karaya and gum kondagogu.
2. Materials and Method
Metformin Hydrochloride was obtained as gift samples from Aurobindo Pharma Ltd, Hyderabad. Gum Kondagogu 
and Gum Karaya  were obtained from Girijan Co-operative Corporation Ltd.,  Visakhapatnam. Methanol,  Potassium Di  
Hydrogen Phosphate, Sodium Hydroxide, Hydrochloric Acid, Barium Sulfate and Sodium Bicarbonate were obtained from 
M/s. Qualigens Fine Chemicals, Mumbai. Magnesium Stearate and Chloroform were obtained from M/s. S. D. Fine-Chem 
Ltd., Mumbai. Poly Vinyl Pyrrolidone was obtained from M/s. Himedia Laboratories Pvt. Ltd., Mumbai. Glycomet – 500 
mg SR tablets (M/s USV Limited, Mumbai; Batch No. 28001178; Mfg. date: 4-2008; Exp. Date: 3-2010) were procured 
from local market.
2.1 Estimation of Metformin Hydrochloride: A spectrophotometric method based on the measurement of absorption at 
extinction 233 nm5 in a 0.1N hydrochloric acid solution was used in the present study for the estimation of metformin 
hydrochloride. 
2.2 Preformulation Studies:  Compatibility studies between metformin hydrochloride and natural gums were studied by 
subjecting the formulation samples to DSC & IR spectral studies.
2.3 Differential Scanning Calorimetry: Differential Scanning Calorimetry (DSC) curves were obtained by a differential 
scanning calorimeter (DSC 220C, Seiko, Tokyo, Japan) at a heating rate of 10OC/min from 30 to 300OC in a nitrogen 
atmosphere 20 mL/min with a sample weight of 3 mg. 
2.4 Infrared Spectroscopic Studies: Fourier–Transform Infrared (FT–IR) spectra were obtained on a Perkin Elmer 2000 
FT–IR system (Perkin Elmer, Norwalk, CT) using the KBr disk method (2 mg sample in 200 mg KBr). The scanning range  
was 400 to 4000 cm-1 and the resolution was 1cm-1. 
2.5 Formulation of Metformin Hydrochloride Tablets: Effervescent type metformin hydrochloride floating drug delivery 
systems were formulated separately with the gum kondagogu and gum karaya. The influence of formulation variables like  
concentration of binding agent, gas-generating agent and concentration of gums on performance of tablet were studied.  
These process variables were optimized and the optimized concentrations of these key excipients were incorporated in the 
final tablet formulations.
In order to study the influence of binder concentration on physical appearance and performance of tablet, different  
concentrations of binding agent poly vinyl  pyrrolidone (2 to 3.5 %w/w) were incorporated. The compositions of these 
tablets are shown in (Table 1) and were formulated by wet granulation technique. The components were blended for 15 min,  
moistened with water to form a damp mass and passed through Sieve No #12 to get granules. The obtained wet granules  
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were dried at 60  OC in hot air oven. Then the granules were passed through Sieve No. #16, lubricated with magnesium 
stearate & talc and compressed as tablet weighing 870mg by using Cadmach 16 station tablet compression machine with 
flat-faced punches (12 mm diameter). Similarly the tablets were formulated with different concentrations of gas generating 
agent (15 to 20 %w/w) sodium bicarbonate, various concentrations (15 to 20 %w/w) of gum kondagogu and gum karaya to 
study the influence of these agents on release rate.
Table 1: Composition of Metformin Hydrochloride Tablets 
Ingredients Quantity (mg) per Tablet
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14
Metformin 
Hydrochloride
500 500 500 500 500 500 500 500 500 500 500 500 500 500
Gum Kondagogu 150 150 150 150 150 150 150 175 125 100 - - - -
Gum Karaya - - - - - - - - - - 150 175 125 100
Sodium Bicarbonate 100 100 100 100 120 150 180 150 150 150 150 150 150 150
PVP K30 10 15 20 25 20 20 20 20 20 20 20 20 20 20
Magnesium Stearate 05 05 05 05 05 05 05 05 05 05 05 05 05 05
Dicalcium Phosphate 105 100 95 90 75 45 15 20 70 95 45 20 70 95
Total Weight 870 870 870 870 870 870 870 870 870 870 870 870 870 870
2.6 Evaluation of Granules:  Metformin hydrochloride granules formulated with various concentrations of binder, gas-
generating agent and gums were subjected to micromeritic studies and other parameters like:
2.6.1 Angle of Repose:  The flow properties of granules were studied by measuring the angle of repose employing fixed 
funnel method. The angle of repose was calculated by using the following formula8.
Where h = height of the pile, cm
r = radius of the base of the pile, cm
2.6.2 Hausner Ratio and Carr’s Index: Hausner ratio and Carr’s index were determined from the poured and tapped bulk 
densities of a known weight of sample using a measuring cylinder.  The following formulas were used for calculating 
Hausner ratio9 and Carr’s Index10
where Dp (poured density) = weight/Vp (poured volume), Dt (tapped density) = weight/Vt (tapped volume).
2.6.3 Moisture Content: Granules (1.0 g) were kept in an oven which was maintained at 105 OC and dried up to constant 
weight. Moisture content was calculated using the following formulae.
2.6.4 Loss on Drying: Granules (1.0 g) were kept in an oven at 105 OC and dried up to constant weight. Loss on drying was 
calculated using the following formulae11.
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2.7 Evaluation of Metformin Hydrochloride Tablets: The formulated tablets were subjected to following quality control 
tests.
2.7.1 Weight Variation: The formulated tablets were tested for weight uniformity. 20 tablets were weighed collectively and 
individually.  From the  collective  weight,  average  weight  was  calculated.  Each  tablet  weight  was  then  compared  with  
average weight to ascertain whether it is with in permissible limits or not. The following formula was used to calculate 
weight variation.
2.7.2  Drug Content: Twenty tablets  were  weighed and  powdered.  The quantity of  powder  equivalent  to  100 mg of 
Metformin Hydrochloride was dissolved in 0.1N HCl, diluted to 100 mL with 0.1N HCl then the solution was filtered and 
the filtrate was suitably diluted with 0.1N HCl. The drug content was estimated spectrometrically at 233 nm12.
2.7.3 Hardness: The tablet crushing strength, which is the force required to break the tablet by compression in the diametric 
direction was measured in triplicate using Pfizer tablet hardness tester13.
2.7.4 Friability: The Roche friability test apparatus was used to determine the friability of the tablets. 20 pre weighed 
tablets  were  placed  in  the  apparatus,  which  was  subjected  to  100 revolutions.  Then  the  tablets  were  reweighed.  The  
percentage friability was calculated using the formula14.
2.7.5 Floating Lag Time: The tablet was placed in dissolution apparatus and the time taken to float on the dissolution  
medium was noted15.
2.7.6 Total Floating Time: The total duration of the time that the tablets float on dissolution medium was noted15.
2.7.7 Swelling Index: The tablet was weighed (Wo) and placed in dissolution medium containing 0.1N HCl maintained at 
37  OC. At 3rd hour, the tablet was withdrawn and blotted to remove excess water and weighed (W t). The percentage of 
swelling index calculated with the following formulae16.
where Wt = weight of the tablet 
at 3rd hour; W0 = weight of the tablet at initial time
2.7.8 Erosion Study: The pre weighed tablets (Wo) were placed in dissolution medium containing 0.1N HCl maintained at 
37 OC. At 4th hour, the tablets were withdrawn and dried in an oven at 105 OC and cooled to room temperature and weighed 
(We). The percentage of erosion (E%) was calculated with the following formula
17.
Where Wo = initial weight of the tablet; 
We = final weight of the tablet
2.7.9 In Vitro Drug Release Studies: Dissolution rate was studied using USP II paddle dissolution apparatus, in 900 ml of  
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0.1N HCl at 37 ± 0.5 OC at 100 rpm. Aliquot of dissolution medium was withdrawn at regular time intervals and the same 
volume of pre-warmed (37 ± 0.5 OC) fresh dissolution medium was replaced. The samples were filtered and drug content of 
metformin  hydrochloride  in  each  sample  were  analyzed  after  suitable  dilution  by  Shimadzu  UV-1700  double  beam 
spectrophotometer (Shimadzu Corporation, Japan) at 233 nm. Further the in vitro drug release studies were also carried out 
with metformin hydrochloride tablets containing 70 mg of metformin hydrochloride, gum kondagogu/gum karaya (18.23 
%w/w), sodium bicarbonate (18.23 %w/w) and PVP (2.31 %w/w).
2.7.10 Determination Of Gastric Retention Period: Evaluation of gastric retention of metformin hydrochloride floating 
tablet  was  preformed  on  rabbit  by the  use  of  radio  opaque  marker  barium sulfate.  X-Ray scintigraphic  identification 
provides a non-invasive method of monitoring total G I residence time without affecting normal G I motility. Healthy rabbit  
of 2.3 ± 0.5 kg was fasted over night and on the next day morning, selected tablet (F6) which was adjusted to rabbit dose 
and containing barium sulfate in place of metformin hydrochloride was administrated followed by giving 25 mL of water. 
At different time intervals of 0, 1, 2, 4, 6 and 8 hours, rabbit G.I.T. was X-Ray photographed and observed for the nature and 
position of the metformin hydrochloride floating tablet18.
2.7.11 Stability Studies: An ideal controlled release dosage form apart from other requirements should provide consistency 
in  drug  release  through  out  its  shelf  life.  The  stability  and  drug  release  from  the  floating  tablets  developed  in  this  
investigation (F6) was also evaluated according to ICH guide lines
19. The selected floating tablets were packed separately in 
the screw capped bottles and stored at 30 OC ± 2 OC/65 %RH±5 %RH. All the products were stored for 6 months. After 6 
months the release of metformin hydrochloride from the stored products were studied separately.
2.7.12  Pharmacodynamic  Studies: Pharmacodynamic  studies  were  carried  out  in  rabbits  separately  for  metformin 
hydrochloride formulations. The blood sugar levels were measured after administration and compared with the standard 
drug to determine the efficiency of the selected formulations. The experimental procedures were discussed below.
3.7.13 In Vivo Evaluation Of Metformin Hydrochloride Floating Tablets: In vivo evaluation studies were conducted on 
metformin hydrochloride tablets and metformin hydrochloride pure drug separately in normal, healthy rabbits (n = 5) by 
measuring serum glucose levels following their oral  administration at a dose equivalent to 35 mg/kg. The tablets were 
reformulated to contain 70 mg of metformin hydrochloride and 2.31, 18.23 and 18.23 %w/w of Poly vinyl pyrrolidone,  
sodium bicarbonate and gum kondagogu/gum karaya respectively for suitable administration to rabbits. The study protocol 
was  approved  by  IAEC  (Institutional  Animal  Ethics  Committee)  before  the  commencement  of  the  study.  In  this 
investigation Latin Square design was employed to minimize subject-subject  variation by keeping one week wash out 
period in between administration of two different formulations and the design was depicted in (Table 2). The standard and  
the selected formulations were administered orally following overnight fasting. The animals were deprived of food during 
the experimental period. The blood samples were collected from the marginal ear vein at 0, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20  
and 24 hrs and analyzed for blood glucose levels with glucose oxidase method20.
Table 2: Experimental Design for Pharmacodynamic Studies of Metformin Hydrochloride Formulations
Subject Formulation Administered
First Week Second Week Third Week
A P F6 F11
B P F6 F11
C P F6 F11
D P F6 F11
E P F6 F11
P= Pure drug Metformin Hydrochloride
 F6 = Metformin Hydrochloride tablets containing 18.23 %w/w gum kondagogu, 18.23 % w/w sodium bicarbonate and 2.31  
%w/w Poly vinyl pyrrolidone
F11 = Metformin Hydrochloride tablets containing 18.23 %w/w gum karaya, 18.23 % w/w sodium bicarbonate and 2.31 %w/w  
Poly vinyl pyrrolidone.
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3. Results
3.1 Preformulation Studies: DSC scans of metformin hydrochloride and drug–excepient mixtures were showed in (Fig. 1a 
to 1c). The DSC scan of metformin hydrochloride showed a short endothermic peak at 236.60OC. The thermo gram of 
tablets formulated with gum kondagogu & gum karaya showed an endothermic peak of drug at 236.70OC and 235.72OC 
respectively indicating no interactions.
Figure 1a, 1b, 1c: DSC Thermograms of Metformin Hydrochloride and pure drug with Gum Kondagogu and Gum 
Karaya
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The IR  spectrum of  metformin  hydrochloride  and  the  formulations  containing  metformin  hydrochloride  were 
showed in (Fig 2a to 2c). The following characteristic bands were observed C=N-(stretching) 1629.55 cm-1, 1655.59 cm-1, 
1669 cm-1,  C-N-(stretching)1061.62 cm-1,  1029.48 cm-1,  1030.77 cm-1,  N-H–(stretching) 3397.96 cm-1,  3378.67 cm-1, 
3394.1  cm-1  in  each  case.  Hence  it  was  concluded  that  there  is  no  chemical  incompatibility  between  metformin 
hydrochloride and the polymers gum kondagogu and gum karaya.
Figure 2a, 2b, 2c: IR Spectra of Metformin Hydrochloride pure drug, with Gum Kondagogu and Gum Karaya
3.2 Studies On Metformin Hydrochloride Floating Tablets
3.2.1 Studies on Binding Agent (PVP): To study the influence of binder on granules and tablet properties the binder PVP 
was incorporated at a concentration ranging from 1 to 3.5 %w/w. The flow properties of these granules were determined and 
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showed in (Table 3) and the physical properties of the tablets were showed in the (Table 4). The granules of formulations F 1 
and F2 exhibited poor flow properties. The tablets formulated with these granules showed high friability values (>1%) and  
hence these formulations were not subjected to in vitro drug release studies. The drug release data from these formulations 
were showed in (Table 6). The release rate followed zero order kinetics and mechanism of drug release was governed by  
peppas  model  and  the  exponential  coefficient  values  were  above  0.5  (Table  5)  indicating  non-Fickian  drug  release. 
Metformin hydrochloride tablets formulated with the binder PVP (2.33 %w/w) was selected for further studies.
Table 3: Physical Properties of Metformin Hydrochloride Granules Formulated with Various Concentrations of Binding Agent
Formulation Average Particle 
Size(μ)
Bulk Density
(g/cm3)
Carr’s
Index
Hausner’s 
Ratio
Angle of 
Repose
Moisture 
Content (%)
Loss on 
Drying (%)
F1 812.34 ± 0.03 0.25 ± 0.05 16.78 ± 0.08 1.46 ± 0.06 32.64 ± 0.01 5.4 ± 0.08 5.1 ± 0.07
F2 937.12 ± 0.03 0.26 ± 0.04 14.28 ± 0.02 1.35 ± 0.06 28.37 ± 0.03 6.5 ± 0.07 6.3 ± 0.05
F3 1036.90 ± 0.05 0.31 ± 0.03 10.10 ± 0.04 1.17 ± 0.03 23.17 ± 0.01 7.6 ± 0.03 7.2 ± 0.02
F4 1149.74 ± 0.06 0.32 ± 0.04 9.94 ± 0.01 1.06 ± 0.03 24.59 ± 0.06 7.7 ± 0.05 7.4 ± 0.07
F5 1047.89 ± 0.04 0.29 ± 0.05 10.55 ± 0.07 1.10 ± 0.02 23.97 ± 0.06 7.8 ± 0.05 7.4 ± 0.02
F6 1062.47 ± 0.08 0.28 ± 0.02 10.86 ± 0.05 1.12 ± 0.02 24.52 ± 0.04 7.9 ± 0.07 7.5 ± 0.02
F7 1068.12 ± 0.06 0.28 ± 0.06 10.78 ± 0.03 1.11 ± 0.04 24.28 ± 0.05 8.2 ± 0.06 7.5 ± 0.03
F8 1089.12 ± 0.05 0.30 ± 0.04 10.12 ± 0.07 1.09 ± 0.05 24.16 ± 0.06 8.6 ± 0.08 8.3 ± 0.06
F9 1029.74 ± 0.06 0.27 ± 0.01 12.05 ± 0.04 1.12 ± 0.02 25.02 ± 0.04 5.8 ± 0.03 5.2 ± 0.04
F10 948.14 ± 0.04 0.26 ± 0.02 13.81 ± 0.03 1.13 ± 0.05 25.19 ± 0.07 5.2 ± 0.07 4.8 ± 0.03
F11 1018.64 ± 0.03 0.22 ± 0.05 9.54 ± 0.01 1.05 ± 0.02 24.28 ± 0.06 6.8 ± 0.04 6.9 ± 0.06
F12 1045.14 ± 0.05 0.26 ± 0.04 9.05 ± 0.02 1.02 ± 0.02 23.35 ± 0.01 7.5 ± 0.02 7.6 ± 0.02
F13 986.84 ± 0.04 0.21 ± 0.02 9.97 ± 0.04 1.09 ± 0.03 24.94 ± 0.04 5.5 ± 0.04 4.9 ± 0.03
F14 945.78 ± 0.04 0.20 ± 0.02 10.51 ± 0.06 1.11 ± 0.05 25.10 ± 0.03 5.0 ± 0.05 4.4 ± 0.04
Table 4: Physical Properties of Metformin Hydrochloride Tablets Formulated with Various Concentrations of Binding Agent
Formulation Weight 
Variation (%)
Drug Content 
(mg)
Hardness
(kg/cm2)
Friability
(%)
Floating Lag 
Time (min)
Floating 
Time (h)
Swelling 
Index (%)
Erosion
(%)
F1 3.36 ± 0.02 499.8 ± 0.01 7.1 ± 0.05 0.95 ± 0.02 20 ± 0.02 > 12 94.07 ± 0.02 8.1 ± 0.05
F2 2.52 ± 0.02 499.6 ± 0.02 7.6 ± 0.01 0.61 ± 0.03 24 ± 0.03 > 12 95.94 ± 0.04 6.9 ± 0.04
F3 2.49 ± 0.06 499.5 ± 0.03 8.4 ± 0.04 0.64 ± 0.03 26 ± 0.02 > 12 96.87 ± 0.02 6.4 ± 0.03
F4 2.86 ± 0.04 499.6 ± 0.04 8.6 ± 0.03 0.56 ± 0.04 27 ± 0.01 > 12 96.92 ± 0.05 6.3 ± 0.04
F5 2.36 ± 0.04 499.4 ± 0.01 8.7 ± 0.02 0.70 ± 0.04 8 ± 0.01 > 12 98.63 ± 0.04 6.7 ± 0.04
F6 2.44 ± 0.03 499.6 ± 0.01 8.8 ± 0.02 0.72 ± 0.05 6 ± 0.01 > 12 102.21 ± 0.05 7.0 ± 0.02
F7 2.56 ± 0.08 496.5 ± 0.05 8.6 ± 0.05 0.91 ± 0.04 4 ± 0.03 > 12 100.86 ± 0.08 6.8 ± 0.05
F8 2.71 ± 0.06 499.3 ± 0.05 8.6 ± 0.07 0.68 ± 0.03 10 ± 0.05 > 12 118.78 ± 0.09 6.6 ± 0.08
F9 2.88 ± 0.04 499.7 ± 0.02 8.5 ± 0.03 0.63 ± 0.05 5 ± 0.02 > 12 94.46 ± 0.03 7.5 ± 0.05
F10 3.06 ± 0.03 499.6 ± 0.02 8.3 ± 0.03 0.73 ± 0.06 5 ± 0.02 > 12 73.49 ± 0.06 8.1 ± 0.01
F11 2.46 ± 0.02 499.5 ± 0.02 8.9 ± 0.01 0.86 ± 0.06 5 ± 0.03 > 12 95.12 ± 0.06 6.9 ± 0.02
F12 2.95 ± 0.01 499.4 ± 0.01 8.4 ± 0.02 0.75 ± 0.05 8 ± 0.01 > 12 109.36 ± 0.05 6.4 ± 0.03
F13 3.12 ± 0.04 499.6 ± 0.02 8.7 ± 0.02 0.82 ± 0.06 3 ± 0.01 > 12 85.49 ± 0.04 7.3 ± 0.04
F14 3.26 ± 0.05 499.6 ± 0.01 8.5 ± 0.03 0.85 ± 0.04 2 ± 0.01 > 12 60.78 ± 0.04 7.8 ± 0.03
# ±S.D
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3.2.2 Studies on Gas Generating Agent:  The effect of gas generating agent sodium bicarbonate was studied with the 
incorporation of  sodium bicarbonate in  the formulation ranging from 15 to 20 %w/w. The micromeritic  properties  of  
granules  were studied and reported in (Table 3).  All  the formulated granules  exhibited good flow and compressibility 
properties. The tablets formulated with these granules were subjected to various quality control parameters and depicted in 
(Table 3, 4). These tablets passed all the quality control tests however difference in the floating lag time was observed from 
these formulations. Floating lag time was found to be decreased with the increased concentrations of gas generating agent.  
The drug release data was showed in (Table 6). The release rate followed zero order kinetics and controlled by non-Fickian  
diffusion. The release kinetics was showed in (Table 5) and release rate constant was treated statistically and significant 
difference in release rate constant between the formulations was observed. The formulation containing sodium bicarbonate 
at 17.25 %w/w offered the required release rate of metformin hydrochloride, Hence it was selected for further studies.
Table 5: Release Kinetics of Metformin Hydrochloride Tablets Prepared with Various Concentrations of Binding 
Agent
Formulation Correlation Coefficient Values Exponential 
Coefficient (n)
Release Rate 
Constant (mg/hr) K0Zero Order First Order Higuchi Model Korsmeyer-Peppas Model
F3 0.9972 0.7725 0.9167 0.9922 1.2740 42.22
F4 0.9966 0.7625 0.9097 0.9923 1.3151 41.46
F5 0.9972 0.7618 0.9236 0.9932 1.2012 43.15
F6 0.9976 0.8166 0.9396 0.9989 0.9890 43.93
F7 0.9987 0.7570 0.9402 0.9995 0.9399 46.47
F8 0.9974 0.9604 0.9168 0.9983 1.0529 28.88
F9 0.9931 0.8284 0.9501 0.9986 0.9258 49.57
F10 0.9962 0.8191 0.9414 0.9986 0.9685 66.78
F11 0.9931 0.8137 0.9496 0.9970 0.9404 45.68
F12 0.9983 0.9379 0.9129 0.9986 1.0223 34.59
F13 0.9883 0.8493 0.9550 0.9981 0.8884 51.00
F14 0.9946 0.8585 0.9469 0.9980 0.9614 76.70
3.2.3 Studies on Gum Kondagogu: To select the required concentration of gum kondagogu, different concentrations of 
gum (15 – 20 %w/w) were incorporated and formulated with wet granulation technique. Prior to compression the granules  
were evaluated for flow properties and showed in (Table 3). All the granules exhibited the required flow and hence they 
were compressed to form tablets. All the tablets were evaluated according pharmacopeias procedures and the data was 
showed in the (Table 4). 
3.2.4 Studies on Gum Karaya: To select the required concentration of gum karaya, different concentrations of gum (15– 
20% w/w)  were  incorporated  and formulated  with wet  granulation technique.  Prior  to  compression the granules  were 
evaluated for flow properties and the results were showed in (Table 3). All the granules exhibited the required flow and 
hence they were compressed to form tablets. All the tablets were evaluated according to official procedures and the data was 
showed in the (Table 4). 
The above tablets  satisfied  all  official  requirements.  The  swelling  index  was  found to  be  increased  with  the  
concentration of gum employed in its preparation. All the formulations were subjected to in vitro drug release studies and 
the data was showed in (Table 6). These formulations followed zero order release and controlled by non-Fickian diffusion.  
The release rate  constant  values  were treated with ANOVA and significant  difference in release rate  was observed in  
between the formulations. Formulation F6 and F11 were selected as best formulation (Table 7), as they offered the required 
release rate of metformin hydrochloride. Good correlation was observed in between release rate constant and swelling index 
(Fig. 3 and 4), as the swelling index is increased the release rate constant was found to be decreased.
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Table 7: Statistical Treatment of Release Rate Constant of Metformin Hydrochloride Tablets Prepared with Different 
Concentrations of Gas Generating Agent
Null Hypothesis (H0): The release rate constant from the tablets formulated with different concentrations of gas generating agents is 
similar.
S No Release Rate Constant (mg/hr) K0
F3 F5 F6 F7
1 42.07 42.97 43.78 46.26
2 42.18 43.15 43.90 46.41
3 42.42 43.32 44.12 46.75
Result: Null hypothesis is rejected, as the calculated value (257.2) at df = 3, 8 and P = 0.01 exceeds the Table value (4.07). Alternative 
hypothesis is accepted, hence indicating the release rate constant obtained with different concentrations of gas generating agents is 
statistically significant.
Different concentrations of gum kondagogu
Null Hypothesis (H0): The release rate constant from the tablets formulated with various concentrations of gum kondagogu is similar.
S No Release Rate Constant (mg/hr) K0
F6 F8 F9 F10
1 43.78 28.61 49.33 66.63
2 43.90 28.86 49.57 66.73
3 44.12 29.17 49.82 66.97
Result: Null hypothesis is rejected, as the calculated value (147.80) at df = 3, 8 and P = 0.01 exceeds the Table value (4.07). Alternative 
hypothesis is accepted, hence indicating the release rate constant obtained various concentrations of gum kondagogu is statistically 
significant.
Different concentrations of gum karaya 
Null Hypothesis (H0): The release rate constant from the tablets formulated with various concentrations of gum karaya is similar.
S No Release Rate Constant (mg/hr) K0
F11 F12 F13 F14
1 45.51 34.35 50.79 76.52
2 45.65 34.55 50.95 76.70
3 45.88 34.88 51.25 76.87
Result: Null hypothesis is rejected, as the calculated value (199.00) at df = 3, 8 and P = 0.01 exceeds the Table value (4.07). 
Alternative hypothesis is accepted, hence indicating the release rate constant obtained with various concentrations of gum karaya is 
statistically significant.
Figure 3: Correlation between Swelling Index and Release Rate Constant of 
Metformin Hydrochloride Tablets Formulated with Gum Kondagogu
Figure 4: Correlation between Swelling Index and Release Rate Constant of 
Metformin Hydrochloride Tablets Formulated with Gum Karaya 
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Table 6: Release Data of Metformin Hydrochloride Tablets Prepared with Various Concentrations of Gas Generating 
Agent
Time 
(h)
Percent Metformin Hydrochloride Released (       ± s.d.)
F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14
0 0 0 0 0 0 0 0 0 0 0 0 0
1 4.15 ± 
0.33
3.86 ± 
0.44
5.17 ± 
0.22
8.67 ± 
0.44
10.20 ± 
0.22
4.81 ± 
0.33
11.52 ± 
0.22
14.36 ± 
0.44
9.47 ± 
0.33
6.56 ± 
0.33
13.05 ± 
0.44
16.26 ± 
0.33
2 10.43 ± 
0.58
9.11 ± 
0.22
11.60 ± 
0.33
18.16 ± 
0.33
21.01 ± 
0.33
11.60 ± 
0.12
21.38 ± 
0.44
26.85 ± 
0.44
22.10 ± 
0.55
14.37 ± 
0.44
22.98 ± 
0.33
32.25 ± 
0.55
3 22.69 ± 
0.44
21.16 ± 
0.27
24.01 ± 
0.44
26.94 ± 
0.34
30.08 ± 
0.46
16.86 ± 
0.33
32.85 ± 
0.55
40.74 ± 
0.77
30.15 ± 
0.44
19.64 ± 
0.66
34.10 ± 
0.44
46.44 ± 
0.55
4 34.97 ± 
0.66
33.00 ± 
0.19
36.51 ± 
0.44
38.42 ± 
0.34
40.18 ± 
0.34
22.50 ± 
0.44
43.76 ± 
0.34
54.35 ± 
0.34
40.91 ± 
0.34
25.20 ± 
0.34
45.51 ± 
0.44
65.16 ± 
0.46
5 42.02 ± 
0.44
40.99 ± 
0.36
45.08 ± 
0.44
46.20 ± 
0.44
47.74 ± 
0.44
27.55 ± 
0.22
54.17 ± 
0.12
70.02 ± 
0.55
49.64 ± 
0.21
32.01 ± 
0.34
55.78 ± 
0.67
79.97 ± 
0.22
6 52.13 ± 
0.31
50.30 ± 
0.11
53.30 ± 
1.08
54.34 ± 
0.12
55.52 ± 
0.34
34.81 ± 
0.34
62.03 ± 
0.34
83.01 ± 
0.33
58.08 ± 
0.13
39.42 ± 
0.44
66.49 ± 
0.55
95.16 ± 
0.44
7 60.50 ± 
0.28
58.16 ± 
0.30
62.04 ± 
0.44
63.01 ± 
0.30
64.92 ± 
0.44
40.17 ± 
0.55
72.38 ± 
0.22
95.87 ± 
0.22
65.44 ± 
0.33
46.97 ± 
0.55
75.61 ± 
0.55
99.42 ± 
0.22
8 68.45 ± 
0.17
67.12 ± 
0.22
70.94 ± 
0.31
72.20 ± 
0.24
73.82 ± 
0.58
45.90 ± 
0.20
81.51 ± 
0.22
99.70 ± 
0.22
76.45 ± 
0.22
54.25 ± 
0.34
85.17 ± 
0.44
---
9 76.62 ± 
0.34
74.86 ± 
0.34
78.39 ± 
0.22
80.38 ± 
0.34
84.33 ± 
0.46
51.21 ± 
0.34
91.74 ± 
0.15
--- 83.47 ± 
0.34
62.11 ± 
0.44
94.17 ± 
0.22
---
10 85.17 ± 
0.22
84.20 ± 
0.44
86.57 ± 
0.13
88.34 ± 
0.13
92.67 ± 
0.13
54.11 ± 
0.34
96.51 ± 
0.29
--- 93.48 ± 
0.44
70.64 ± 
0.67
98.50 ± 
0.19
---
11 93.21 ± 
0.44
91.88 ± 
0.22
95.13 ± 
0.27
96.03 ± 
0.28
99.77 ± 
0.19
64.82 ± 
0.66
99.68 ± 
0.30
--- 98.32 ± 
0.22
77.65 ± 
0.34
99.71 ± 
0.13
---
12 99.66 ± 
0.09
99.64 ± 
0.30
99.83 ± 
0.17
99.42 ± 
0.10
--- 72.99 ± 
0.88
--- --- 99.75 ± 
0.10
85.25 ± 
0.46
--- ---
3.3 Comparative studies on Metformin Hydrochloride Tablets Prepared with Gum Kondagogu and Gum Karaya: To 
compare the effect of the gums on the release rate of metformin hydrochloride from the tablets, the formulations containing 
equal concentration of the polymers, gas generating agents and binder were subjected to in vitro release studies (F6 & F11). 
The drug release data of these two formulations was showed in the (Table 6). These two formulations followed zero order  
release and followed non-Fickian model. The release rate constant values were treated (Table 5) with unpaired t-test and 
significant difference in release rate was observed in between the formulations.  Gum kondagogu offered much slower  
release rate of Metformin hydrochloride. Hence it is more suitable for design and development of oral sustained release  
formulations of Metformin hydrochloride. The difference in the release rate constant values from these two gums may be  
attributed due to the difference in viscosities and swelling index contributed by these two gums.
The swelling index values observed in 0.1N HCl at 3rd hour from the floating tablets containing same composition 
of excipients with variation only in nature of gum (either gum kondagogu and gum karaya) was 102.21 ± 0.05 and 95.12 ±  
0.06 from gum kondagogu and gum karaya formulations respectively.
The  viscosities  of  1  %w/v  aqueous  dispersions  of  gum  kondagogu  and  gum  karaya  were  determined  with 
Brookfield viscometer (DV – III Ultra). The viscometer was operated with spindle no. SC4-18 at a shear rate of 79.20 to 
132.00 by employing small sample adapter (8 mL capacity). The viscosity values were analyzed with Rheocalc software.  
The data was fitted in bingham’s plot. To compare the viscosities the gums were analyzed at a same shear rate and at room 
temperature. The viscosity values observed with gum kondagogu are relatively higher than gum karaya (Table 9).
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Figure 5: Comparative Release Profiles of Metformin Hydrochloride Tablets Prepared with Gum Kondagogu and 
Gum Karaya
4.4  Comparison  of  the  Metformin  Hydrochloride  Tablets  Prepared  with  Gum  Kondagogu  and  Marketed 
formulation:  The drug  release  rate  from the  selected  formulation  (F6)  was  compared  with  the  marketed  formulation 
(Glycomet SR, 500 mg). The corresponding release data was showed in (Table 6) and (Fig. 6). Both formulations followed 
zero order kinetics and controlled by non-Fickkin diffusion. The release kinetics were showed in (Table 8) and treated  
statistically with unpaired t test. They were found to be different in release characteristics. The formulation developed in this  
investigation offered a much slower release rate of Metformin hydrochloride.
Fig 6: Comparative Release Profiles of Selected Metformin Hydrochloride Tablets (F6) and Marketed Formulation
Table 8: Comparative Release Kinetics of Selected Metformin Hydrochloride Tablets (F6) and Marketed 
Formulation
Formulation Correlation Coefficient Values Exponential 
Coefficient
(n)
Release Rate 
Constant
(mg/hr) K0Zero Order First Order Higuchi Model
Korsmeyer-
Peppas Model
F6 0.9976 0.8166 0.9396 0.9989 0.9890 43.93
Marketed 0.9925 0.8355 0.9595 0.9979 0.8370 66.15
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3.5 Influence of pH on Viscosity and Swelling Index: To study the influence of pH on swelling index about 1 g of gum 
was dispersed in 15 ml of pH 7.4 phosphate buffer or 0.1N Hydrochloric acid separately. The gums were collected at 3 rd 
hour and reweighed. The swelling index values were calculated from the initial and final weight. The % swelling index  
observed with gum kondagogu in pH 7.4 phosphate buffer and 0.1N Hydrochloric acid were found to be 92.18 and 74.23% 
respectively. The swelling index was found to be more in alkaline conditions than acidic conditions. Similar results were  
also noticed with gum karaya (in pH 7.4 phosphate buffer 86.67 and 68.47% swelling index in 0.1N Hydrochloric acid).
The influence of pH on viscosity was carried out by subjecting 1 %w/v of gum dispersions for rheological studies.  
The viscosities noticed with gum kondagogu dispersions formulated with pH 7.4 phosphate buffer and 0.1N Hydrochloric 
acid at room temperature were 36.4 cP and 5.43 cP respectively. Gum karaya dispersions (1 %w/v) formulated with pH 7.4 
phosphate  buffer  and  0.1N HCl showed 10.7  cP and 3.99 cP respectively at  same temperature  (Table  9).  Thus  these  
rheological studies clearly reveals that the viscosity of these dispersions were relatively much higher in alkaline conditions.  
It may be attributed due to the activation acetyl groups possessed by these gums. These gums consist of high molecular  
weight acetylated poly saccharides (20), which are likely to be suppressed in acidic conditions and they may be activated in  
alkaline conditions. It  was concluded that more sustained release of active ingredients from these gum matrices can be  
achieved in alkaline conditions.
Table 9: Rheological Properties of Gum Kondagogu and Gum Karaya in 0.1N HCl
Speed (RPM) Torque (%) Shear Rate (1/sec) Shear Stress (D/cm2) Viscosity (cP)
Gum Kondagogu
60.00 49.51 79.20 19.60 24.74
70.00 51.74 92.40 20.47 22.15
80.00 53.62 105.60 21.22 20.10
90.00 54.97 118.80 21.78 18.33
100.00 56.90 132.00 22.53 17.07
Yield Stress (D/cm2): 15.4 Confidence of Fit: 99.7 Plastic Viscosity (cP): 5.43
Gum Karaya
60.00 21.04 79.20 8.31 10.50
70.00 22.83 92.40 9.03 9.77
80.00 24.52 105.60 9.70 9.19
90.00 25.94 118.80 10.25 8.63
100.00 26.13 132.00 10.33 7.83
Yield Stress (D/cm2): 5.31 Confidence of Fit: 98.3 Plastic Viscosity (cP): 3.99
3.6 Comparative Studies of Metformin Hydrochloride Tablets Formulated for Human Use and Usage in Rabbits: The 
formulated tablets containing 500 mg of metformin hydrochloride were weighing around 823 mg which found difficult to 
administer in rabbits. So, the tablets were reformulated to contain 70 mg of metformin hydrochloride (calculated dose for  
rabbits) with the same proportion of other excipients to obtain a tablet weight of 115.22 mg for convenient administration in  
rabbits by compressing with 5 mm diameter of die.
The drug release rate is likely to be influenced by the geometry of the tablet dosage form. The reformulated tablets  
were subjected to drug release studies and the data was compared with the formulations containing 500 mg of metformin  
hydrochloride (Fig. 7). The observed similarity factor was 76.58 thus indicating that these two formulations possess an 
identical release profiles. Similar results were also observed with gum karaya as a similarity factor of 76.16 was observed 
(Fig. 8). Hence these two newly formulated tablets were subjected to X-ray studies to identify the position of tablet in GIT 
and for pharmacodynamic studies to determine the efficacy of dosage form in reduction of blood sugar levels.
Raparla et al / International Journal of Advances in Pharmaceutics  1 (1) 2012                                                                  35 
3.6.1  Estimation  of  Gastric  Resident  Time  of  Metformin  Hydrochloride  Floating  Tablets:  GI  Residence  Time 
associated with the administration of kondagogu floating tablet containing barium sulphate (free from drug) was determined 
by X-ray photographs (Fig. 9). The X-ray studies showed that the floating tablets formulated with metformin hydrochloride 
and gum kondagogu remained in the gastric region even after 10 hours of administration indicating good retention of the  
tablets in the stomach region.
Figure 9: X-Ray Photographs of Following Administration of Floating Tablets Containing Gum Kondagogu and 
Barium Sulfate
Figure 7: In Vitro Release Profiles of Metformin 
Hydrochloride Tablets Containing 70 mg of Metformin 
Hydrochloride and having Composition Similar to F6
Figure 8: In Vitro Release Profiles of Metformin Hydrochloride 
Tablets Containing 70 mg of Metformin Hydrochloride and 
having Composition Similar to F11
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3.7  Stability  Studies:  The  stability  in  drug  release  profiles  was  conducted  according  to  ICH  guidelines.  Metformin 
Hydrochloride floating tablets formulated with either 18.23 %w/w of gum kondagogu or gum karaya along with 2.31 %w/w 
binder poly vinyl pyrrolidone and 18.23 %w/w gas generating agent sodium bicarbonate were packed separately in a screw 
capped bottle and subjected to stability studies according to ICH guidelines. The drug release profiles were presented in  
(Table 10, 11). These profiles showed good stability of release from the floating tablets and it was supported by similarity 
factor value 74.23 & 71.06.
Table 10: Release Data of Metformin Hydrochloride Floating Tablets (F6) Formulated with Gum Kondagogu Kept at 30
OC ± 
2OC/65 %RH ± 2 %RH
Time (h) MDT (T)/
MDT (R)
AUC (T)/
AUC (R)
Initial 6th Month
0 0 0 0 0
1 8.67 ± 0.44 5.98 ± 0.33 1.000 0.689
2 18.16 ± 0.33 14.59 ± 0.22 1.066 0.747
3 26.94 ± 0.34 23.65 ± 0.33 1.084 0.804
4 38.42 ± 0.34 34.99 ± 0.44 1.065 0.845
5 46.20 ± 0.44 42.39 ± 0.33 1.051 0.871
6 54.34 ± 0.12 50.61 ± 0.22 1.049 0.887
7 63.01 ± 0.34 59.05 ± 0.34 1.041 0.900
8 72.20 ± 0.44 68.24 ± 0.22 1.039 0.909
9 80.38 ± 0.23 77.58 ± 0.34 1.050 0.919
10 88.34 ± 0.13 85.54 ± 0.46 1.044 0.928
11 96.03 ± 0.34 93.81 ± 0.34 1.045 0.935
12 99.42 ± 0.13 97.63 ± 0.33 1.047 0.942
Table 11: Release Data of Metformin Hydrochloride Floating Tablets (F11) Formulated with Gum Karaya Kept at 30 
OC ± 2 
OC/65 %RH ± 2 %RH
Time (h) MDT (T)/
MDT (R)
AUC (T)/
AUC (R)Initial 6th Month
0 0 0 0 0
1 9.47 ± 0.33 6.27 ± 0.22 1.000 0.661
2 22.10 ± 0.55 18.75 ± 0.22 1.088 0.762
3 30.15 ± 0.44 27.52 ± 0.44 1.095 0.831
4 40.91 ± 0.34 36.38 ± 0.34 1.033 0.860
5 49.64 ± 0.21 44.30 ± 0.33 1.025 0.871
6 58.08 ± 0.13 53.03 ± 0.44 1.038 0.881
7 65.44 ± 0.33 60.38 ± 0.33 1.040 0.890
8 76.45 ± 0.22 72.92 ± 0.34 1.058 0.901
9 83.47 ± 0.34 80.59 ± 0.22 1.060 0.913
10 93.48 ± 0.44 89.51 ± 0.33 1.039 0.922
11 98.32 ± 0.22 95.66 ± 0.44 1.052 0.929
12 99.75 ± 0.10 98.54 ± 0.13 1.067 0.937
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Pharmacodynamic Studies
3.8 Studies on floating tablets of Metformin hydrochloride: In vivo evaluation of the Metformin hydrochloride floating 
tablets containing 70 mg metformin hydrochloride and having a percent composition of other excipients similar to F6 and 
F11 was carried out separately in healthy, normal rabbits by measuring the hypoglycemic effect produced after their oral  
administration. The blood sugar levels observed with the administration of the standard and test product were showed in  
(Fig. 10). When pure Metformin hydrochloride was administered as a standard (aqueous suspension containing 1 mg/mL), a 
rapid reduction in serum glucose levels was observed; a maximum reduction of 56.8% was observed at 1.0 hours after  
administration, and the glucose levels  recovered rapidly to  the normal  level  after  a period of  4  hours.  In  the case of  
formulation containing gum kondagogu, the maximum reduction (52.49%) in blood glucose levels was observed at 2nd hour 
and the effect was found to be sustained up to 14th hour which is shown in (Fig. 11). In the case of formulation containing 
gum karaya, the maximum blood glucose levels was observed at 1.5
th hour and sustained effect was observed till 12th hour. 
The sustained hypoglycemic effect observed over longer periods of time in the case of floating tablets prepared with gum  
kondagogu which may be due to the slow release and absorption of metformin hydrochloride. As the hypoglycemic effect of  
metformin hydrochloride is sustained over a period of 14 hours with the formulation prepared with gum kondagogu, hence  
it is more suitable than the formulation prepared with gum karaya.
Thus these pharmacodynamic studies indicated that the formulations containing gum kondagogu are more suitable 
maintenance of blood glucose levels for an extended period of time than formulations prepared with gum karaya as both  
microcapsules  and  floating  tablets  containing  gum  kondagogu  showed  more  sustained  hypoglycemic  affect  than  the 
formulations containing gum karaya.
4. Discussion
Studies were carried out on floating tablets of metformin hydrochloride formulated with gum kondagogu and gum 
karaya. The influence of binding agent, gas generating agent on flow properties of granules, floating nature of tablet and on 
drug release were studied. Drug and polymer interaction studies were carried out with DSC and IR spectra. The stability of  
the drug release from gum kondagogu and gum karaya floating tablets and microcapsules developed in the investigation was 
studied as per ICH guidelines.
The selected floating tablets and the microcapsules were subjected to pharmacodynamic studies. The study was 
carried in 4 diurnally active normal, healthy rabbits and performed with Latin Square design, allowing a wash out period of  
one week between each treatment. Blood glucose levels and percent reduction in blood glucose levels were determined.
The  results  related  to  the  floating  tablets  indicated  that  the  concentration  of  binding  agent  employed  in  the  
Figure 10: Blood Glucose Levels Following the Administration of 
Metformin Hydrochloride and its Floating Tablets
Figure 11: % Reduction of Blood Glucose Levels Following the 
Administration of Metformin Hydrochloride and its Tablets
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formulation influences the flow properties of the granules and mechanical strength of the tablet. The floating time was 
found to be highly influenced by the gas generating agent concentration. The drug release rate was found to be affected with  
concentration of gum employed in the preparation of floating tablets. Gum kondagogu was found to be a good matrix 
forming  material  for  controlled  release.  The  resulting  tablet  provided  slow  and  controlled  release  of  metformin  
hydrochloride over 12 hrs. Drug release from the floating tablets can be controlled by changing the amount of gum, gas  
generating agent and swelling index. The floating tablets exhibited good sustained release characteristics both in vitro and 
in vivo. Hence these floating tablets are recommended for oral controlled delivery of metformin hydrochloride. Thus the 
present investigation resulted in the development of floating tablets for oral controlled delivery of metformin hydrochloride 
fulfilling the other objective of the investigation.
5. Conclusion
Metformin hydrochloride found compatible with gum kondagogu and gum karaya with this work. The size and 
flow properties of granules are influenced by the binding agent concentration. Gas generating agent concentration controls  
the floating properties of the tablets. The rate of drug release decreases with the increase in concentration of the gum 
employed in the preparation of the tablet. The required release rate from the floating tablets can be readily obtained by 
changing the concentration of gas generating agent and the polymer. Gum karaya offers rapid release rate when compared 
with gum kondagogu in the concentration of 17.25% w/w. The floating tablets formulated with these two gums are quite 
stable.
The  floating  tablets  formulated  with  gum kondagogu  are  more  suitable  to  control  blood  sugar  levels  for  an 
extended period of time. Thus all the major objectives of this investigation were fulfilled and appropriately placed in this 
article.
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